Ziftomenib

Technology

Last mentioned: Mar 6, 2026

Timeline

  1. PROF Break-even

    Target window for Profound Medical to reach cash-flow neutrality.

  2. Kura NDA Submission

    Anticipated filing for ziftomenib with the FDA.

  3. Q4 Earnings Release

    Both companies report pivotal year-end results.

  4. CPT Code Activation

    Category 1 CPT codes for TULSA-PRO go live in the U.S.

Stories mentioning Ziftomenib 1

earnings Neutral

Kura and Profound Signal Commercial Inflection Points in Q4 Results

Kura Oncology and Profound Medical reported Q4 2025 results, highlighting a pivotal shift toward commercial execution. Kura is nearing an NDA submission for its lead leukemia candidate, while Profound saw record revenue growth following the first full year of Category 1 CPT code implementation.

2 sources